ABSTRACT
A global health pandemic that began in December 2019 was the newSARS-CoV-19 coronavirus. The bioactivities of the heterocyclic drug triazavirin selected have been assessed in this study using computer modelling strategies as inhibitors and nucleotide analogs for COVID-19. Triazavirin is an antiviral drug that is synthesized with triazavirin (2-methylsulfanyl-6-nitro[1,2,4]triazolo[5,1-C][1,2,4]triazine-7(4H)-one, TZV). For potential requirements against the 2019-nCoV Coronavirus, TZV is being investigated. We have conducted a computerized study for the screening of effective Triazavirin (C 5H4N6O3S) available medication which can be inhibitors for the Mpro of 2019-nCoVin order to find candidate drugs for the 2019-nCoV period. In the present work, (DFT/TD-DFT/B3LYP/6-31 G(d,p)) calculations have been carried out first of all for the purposes of estimating the thermal parameters, dipole momentum, polarization, and molecular power of the drug currently in the gas stage of the molecular structure of the title molecules. The studied compound has also calculated and shown its molecular HOMO-LUMO, its excitation energy, and its oscillator strengths. DFT and TD-DFT studies have been conducted to interact the TZV compound with the Coronavirus. Thus, TZV can be applied for possible application against Coronavirus 2019-nCoV applications.
ABSTRACT
The coronavirus (COVID-19) is a global public health pandemic disease emerged from the novel strain of the coronavirus 2 (SARS-CoV-2) that caused severe acute respiratory syndrome. It is the most significant respiratory illness that has affected the world since World War II. Currently, there is no globally approved drug for the treatment of pandemic COVID-19 except for some recently approved vaccines. Instead, various non-specific treatment options are being utilized by different countries. While some of these are effective, there is a lack of well-documented studies on the impact of traditional medicines on the management of SARS-CoV-2 in vitro and in silico. For thousands of years, traditional healers have been using various herbs and spices products and dietary plants to treat various diseases. This review aims to provide information on the use of traditional spices & herbs in COVID-19 protection and treatment and present the main characteristics of these products and their potential antiviral actions. Various databases were searched for articles related to the use of various herbs for the treatment of viral infections. Many of these studies show that various plant compounds can be utilized for the treatment of viral infections. This study aims to summarize the common used of herbal products and dietary supplements with potent bioactive compounds in treatment or prevent of COVID-19.
ABSTRACT
For the third year COVID-19 pandemic is still a global health challenge, despite the availability of vaccines and protection methods, treatment protocols still being updated continuously to observe the optimum management for patients. Cyclooxegynase (COX) enzymes are involved in inflammation and thrombosis related to COVID-19. COX-Thromboxane2 pathway is one of the important pathways that results in thrombus formation. In this study the COX activity level changes were measured by ELISA technique in COVID-19 plasma samples that treated with SIRT1 activators resveratrol and linear BAS SIRT1 aptamer, a significant lowering in COX activity was observed with promising potential atrithrombotic action in COVID-19 to be further investigated in future.
ABSTRACT
The article discusses that the researchers examined the susceptibility of two Omicron BA.4.6 isolates to available antiviral drugs and monoclonal antibodies. The results indicate that prevalent SARS-CoV-2 variants are increasingly resistant to therapeutic and prophylactic monoclonal antibodies but remain susceptible to Paxlovid, remdesivir, and molnupiravir.
ABSTRACT
Objective: This study aimed to evaluate the adverse effects of hydroxychloroquine (HCQ) in children with COVID-19. Material and Methods: This study was conducted between MarchAugust 2020 at a referral tertiary hospital for pediatric infectious diseases in the Aegean Region of Turkey. All hospitalized children with COVID-19 who were received HCQ include in this study. An electrocardiogram (ECG) was performed prior to the initiation of HCQ and at certain times (first and 24th hours of HCQ administration and two hours after the final dose of HCQ) during treatment. Adverse effects associated with HCQ were evaluated during the hospitalization and also the first and second months after discharge. Results: A total of 62 children with COVID-19 who administered HCQ treatment were evaluated. Of these, 35 (56.5%) were girls and 27 (43.5%) were boys. The mean age 13.7 ± 3.0 years (range 6.0 to 18.0 years). Prior to the admission, none of the patients had arrhythmia, cardiovascular disease, or any cardiotoxic drugs usage. There was no abnormality on the baseline and following ECGs during the treatment with HCQ. Thirteen patients had nausea (20.9%) and 10 patients (17.7%) had mild abdominal pain. None of the patients had no arrhythmia. Conclusion: No cardiac side effects were observed in our patients. However, it is not possible to give a general statement on the safety data of HCQ therapy without any randomized controlled large-scale studies.
ABSTRACT
New drug approved for rare enzyme deficiency genetic disorder... New treatment for generalized pustular psoriasis... Nitric oxide may help patients who are pregnant and have COVID-19 pneumonia... Opioid prescriptions decreased between 2012 and 2019... Two-drug strategy confers benefits and risks for patients undergoing coronary artery bypass graft surgery
ABSTRACT
Paxlovid drug interaction... Eprontia oral solution concentration conversion... Different concentrations of oral liquid Baclofen
ABSTRACT
The article offers information on monoclonal antibody infusion service for obstetric women infected with Covid-19. It mentions that monoclonal antibody (MAB) infusions were approved under an emergency use authorization for treatment of mild to moderate Covid-19 infection in adults and pediatric patients.